COMPANY NEWS

More

Latest Progress of BuMA Supreme™ released at CIT2015
The 13th China Interventional Therapeutics Conference (CIT) has taken place in Beijing National Conference & Exhibition Center between 19th and 22th March. On 21th March, China hosted its Luncheon Symposium where the topics mainly focused on the late breaking results of BuMA and BuMA Supreme. Next to prof. Patrick W. Serruys, prof. Renu Virmani, prof. Junbo Ge and Dr. Jianping Li,China has invited Key Opinion Leaders (prof. Yong Huo, prof. Huay Cheem Tan, prof. Robaayah Zambahari, prof. Rosli Mohd Ali and prof. Teguh Santoso) from China and south-east Asia to co-chair the session.

During this session, Dr. Jianping Li from Peking University First Hospital shared a systematic overview on endothelium functional healing. A new concept named ‘the window of opportunity hypothesis’ was introduced and discussed in this session. With this presentation, Dr. Jianping Li aimed to clarify the process of endothelium restoration and provide the benefit of BuMA from a perspective of vascular restoration. This concept entails that complete functional endothelial healing is required to prevent late stent thrombosis in the long-term. In order to achieve this, functional endothelium healing need to be achieved within a certain period.

Furthermore, Dr. Jianping Li provided an overview on all BuMA Series clinical trials. PANDA III is a post-market RCT trial where the enrollment has completed in September 2014. The primary endpoint of this trial is 1 year TLD including cardiac death, target vessel MI and clinical driven TLR. One year result is anticipated to confirm the concept ‘the window of opportunity’.

Prof. Renu Virmani and prof. Patrick W. Serruys provided latest information on BuMA Supreme. BuMA Supreme is the 2nd generation DES of China where a platform alteration is made (from 316L to CoCr). Prof. Serruys provided insights and updates on the FIM trial called PIONEER in Europe. This FIM trial is a multi center trial including 13 sites in the Netherlands, Belgium, Spain and Portugal. The first patient enrolment will take place by end of March 2015.

BuMA (1st generation) has been implanted in China (130.000) with superior clinical results. It is considered by Chinese cardiologists as the safest coronary stent presently available on the market, both in terms of success rate of implantation and in terms of long terms acceptance and safety for patients.

NEWS

More

Luncheon Symposium CIT 2013
During CIT 2013 on 28th March, Beijing hosted its Luncheon Symposium named: ‘From China to US, how long does it take to reach perfect endothelialization?’. The latest results of OCT analysis of a 12 month comparative study were released. This symposium was chaired by Prof. Bo Yu from 2nd affiliated hospital of Harbin Medical University and Prof. Shubin Qiao from Fuwai hospital CAMS & PUMC.

A follow-up on CIT 2012 compared the results of 3 and 12 months on the endothelialization process between BuMA™ and XIENCE V. Considerable publicity was generated for its unique trial design comparing BuMA™ to XIENCE V and implanting both types of stents in the same lesion, vessel and patient in order to reduce blood vessel variances. Dr. Jingbo Hou from the 2nd affiliated Hospital of Medical University of Harbin has released significant and outstanding 12 month results with BuMA™ reaching superior outcomes in strut coverage. Parameters such as malapposition, protruding and embedding were all significantly better for BuMA™ after 12 month observation. (Click here for more information on this study)

Furthermore, Dr. Renu Virmani from CVPath in U.S revealed her OCT swine coronary analysis comparing BuMA™ with XIENCE V. The design of the study was the same as with human OCT analysis conducted by Jingbo Hou, M.D. In this research, both BuMA™ and XIENCE V showed complete endothelialization in 45 days, and also excellent neointimal coverage even after 14 days. Also, all histological parameters were comparable between BuMA™ and XIENCE V. Finally, OCT analysis has shown accurately measured neointimal thickness with excellent correlation with histology.

ABOUT US

More

Company
Shanghai crown medical instruments Co., Ltd as a subsidiary of AM CROWN HOLDING GROUP,was established in 1999, which set the headquarter in Shanghai and set factories in Hanzhong city,Guangyuan city, …
PRODUCTS
友情链接: 葡京现金开户 葡京免费开户 娱乐葡京开户 ag葡京官网 葡京官网ag 线上葡京注册 澳门线上葡京 葡京开户试玩 葡京公司娱乐 葡京电子开户 葡京亚洲开户 葡京官网扑克 葡京彩票官网 葡京手机投注 葡京真人赌博 葡京账号注册 葡京赌场棋牌 葡京百家乐 线上葡京真人 葡京国际棋牌 葡京网站游戏 澳门葡京网络 葡京导航 澳门葡京导航 葡京现金网址 葡京开户赌场 葡京官方地址 葡京娱乐总代 彩票网站葡京 葡京彩票app 王者葡京官网 葡京博彩代理 葡京登录 澳门葡京登录 葡京线路检测 正规葡京线上 葡京赌钱 澳门葡京赌钱 葡京投注app 葡京mg网址 葡京体育 澳门葡京体育 葡京体育网站 葡京体育平台 葡京体育注册 葡京网页版 葡京赌场app 葡京网站注册 葡京提现 澳门葡京提现 葡京网址大全 葡京国际app 葡京网投平台 葡京手机网站 葡京真人注册 葡京外围 澳门葡京外围 葡京盘口 澳门葡京盘口 葡京彩票娱乐
友情链接: 葡京现金开户 葡京免费开户 娱乐葡京开户 ag葡京官网 葡京官网ag 线上葡京注册 澳门线上葡京 葡京开户试玩 葡京公司娱乐 葡京电子开户 葡京亚洲开户 葡京官网扑克 葡京彩票官网 葡京手机投注 葡京真人赌博 葡京账号注册 葡京赌场棋牌 葡京百家乐 线上葡京真人 葡京国际棋牌 葡京网站游戏 澳门葡京网络 葡京导航 澳门葡京导航 葡京现金网址 葡京开户赌场 葡京官方地址 葡京娱乐总代 彩票网站葡京 葡京彩票app 王者葡京官网 葡京博彩代理 葡京登录 澳门葡京登录 葡京线路检测 正规葡京线上 葡京赌钱 澳门葡京赌钱 葡京投注app 葡京mg网址 葡京体育 澳门葡京体育 葡京体育网站 葡京体育平台 葡京体育注册 葡京网页版 葡京赌场app 葡京网站注册 葡京提现 澳门葡京提现 葡京网址大全 葡京国际app 葡京网投平台 葡京手机网站 葡京真人注册 葡京外围 澳门葡京外围 葡京盘口 澳门葡京盘口 葡京彩票娱乐